Literature DB >> 9870197

Evaluation of a novel bioprosthetic heart valve incorporating anticalcification and antimicrobial technology in a sheep model.

D Langanki1, M F Ogle, J D Cameron, R A Lirtzman, R F Schroeder, M W Mirsch.   

Abstract

BACKGROUND AND AIM OF THE STUDY: The St. Jude Medical (SJM) Epic valve has been designed to diminish the risk of prosthetic valve endocarditis by the use of silver-coated polyester fabric, and to inhibit dystrophic calcification by the use of ethanol pretreatment.
METHODS: A 20-week juvenile sheep mitral valve implant model was used to determine safety and efficacy of the device, as well as the rate of silver release and degree of dystrophic calcification. The SJM Epic valves were compared with SJM Biocor porcine valves (not ethanol-pretreated, not silver-modified polyester fabric) and Baxter Carpentier-EdwardsR standard valves.
RESULTS: Blood concentrations of silver reached a maximum of 40 p.p.b. within 10 days of SJM Epic valve implantation, and were well below toxic levels (300 p.p.b.). Blood silver concentrations returned to baseline within 30 days after surgery. Maximal silver accumulation occurred in the liver (16.75 mg/g dry weight); concentrations in the brain, spleen, kidney and lung were similar to those reported for other silver-modified prosthetic valves. No statistically significant difference was found in calcium content between SJM Epic and Biocor valves. The fibrous response to the sewing cuff was similar among the three valve types.
CONCLUSIONS: At all times tested, silver release from the SJM Epic valve led to blood concentrations well below toxic levels. Although calcification in the two SJM valve groups was extremely low, the 20-week sheep model may be insufficiently sensitive to detect differences in calcium accumulation in modern bioprosthetic valves.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9870197

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  5 in total

Review 1.  A glimpse of hope: cardiac surgery in low- and middle-income countries (LMICs).

Authors:  Peter Zilla; R Morton Bolman; Percy Boateng; Karen Sliwa
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

2.  Assessing anticalcification treatments in bioprosthetic tissue by using the New Zealand rabbit intramuscular model.

Authors:  Gregory A Wright; Joelle M Faught; Jane M Olin
Journal:  Comp Med       Date:  2009-06       Impact factor: 0.982

3.  Preventing Implant-Associated Infections by Silver Coating.

Authors:  Richard Kuehl; Priscilla S Brunetto; Anne-Kathrin Woischnig; Massimo Varisco; Zarko Rajacic; Juerg Vosbeck; Luigi Terracciano; Katharina M Fromm; Nina Khanna
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

4.  A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices.

Authors:  Alan B G Lansdown
Journal:  Adv Pharmacol Sci       Date:  2010-08-24

5.  Antibacterial abilities and biocompatibilities of Ti-Ag alloys with nanotubular coatings.

Authors:  Xingwang Liu; Ang Tian; Junhua You; Hangzhou Zhang; Lin Wu; Xizhuang Bai; Zeming Lei; Xiaoguo Shi; Xiangxin Xue; Hanning Wang
Journal:  Int J Nanomedicine       Date:  2016-11-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.